EGFRvIII+ GBM cells displayed increased cleaved PARP compared to GBM22 EGFR WT or parental GBM22 (Figure 4A), as well as increased accumulation of annexin V when treated with saracatinib and TMZ (Figure 4B,C). This evidence concerns the gene ANXA5 and glioblastoma.